Med. Pro Praxi 2008; 5(12)

Slovo úvodem

Published: December 19, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Slovo úvodem. Med. praxi. 2008;5(12):.

Vážení čtenáři,

na konec roku jsme si pro vás připravili překvapení. Místo obvyklého čísla časopisu Medicína pro praxi se vám dostává do rukou speciální brožurka Urologická problematika v praxi.

Najdete v ní aktuální a přehledné informace o nejčastějších onemocněních, které přivádějí pacienty do vašich ordinací. Doufáme, že tato novinka bude vítaným zpestřením, které ve své praxi využijete.

Na tomto místě bychom také rádi poděkovali všem, kteří se podíleli na vytváření časopisu v letošním roce a přispěli tak svou odborností, zkušenostmi a pílí ke zvyšující se kvalitě. V novém roce pro vás chystáme několik novinek, z nichž nejvýraznější bude nový vzhled časopisu. Určitě vás zaujme.

Klidné a pohodové Vánoce a jen příjemná překvapení v novém roce přeje

Redakce

Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bailey RR. Management of lower urinary tract infections. Drugs 1993; 45(Suppl 3): 134-139. Go to original source... Go to PubMed...
    2. Bartoníčková K. Infekce močových cest u urologických nemocných. In: Teplan V, Horáčková M, Bébrová E, Janda J a kol. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing, 2004: 127-151.
    3. Bartoníčková K. Nespecifické močové infekce. In: Dvořáček J a kol.: Urologie, díl II, Praha ISV, 1998: 683-738.
    4. Bartoníčková K. Uroinfekce. Praha: Galén 2000.
    5. Bishop MC. Uncomplicated urinary tract infection. EAU Update Series 2004; 2: 143-150. Go to original source...
    6. Brown JS, Vittinghoff E, Kanaya AM et al. Urinary tract infection on postmenopauzal women: effect of hormone therapy and risc factors. Obstet Gynecol 2001; 98: 1045-1052. Go to original source... Go to PubMed...
    7. Harding GKM, Donald AR, Nicolle LE, Thomson MJ, Gray GJ. Long-term antimicrobial prophylaxis for recurrent UTI in women. Rev Infect Dis 1982; 4: 438-443. Go to original source... Go to PubMed...
    8. Horáčková M. Infekce močového traktu u dospělých. In: Teplan V, Horáčková M, Bébrová E, Janda J a kol. Infekce ledvin a močových cest v dospělém a dětském věku. Praha: Grada Publishing 2004: 63-91.
    9. Chmel R. Močová infekce a inkontinence u žen v postmenopauze. Lék listy 2003; 38: 19-22.
    10. Kolombo I, Berndt D, Pabišta R, Smetana L, Porš J a kol. Problémy současných STD v naší urologické praxi. Urolog pro praxi 2004; 5: 29-30.
    11. Kolombo I. Nekomplikované uroinfekce-co je nového a co se změnilo. Urol List 2005; 2: 13-29.
    12. Krieger JN. Urinary tract infections: What´s new? J Urol 2002; 168: 2351-2358. Go to original source... Go to PubMed...
    13. Matoušková M, Rollová M. Imunomodulace probiotiky v léčbě recidivujících zánětů dolních močových cest. Čes urol 2001; 4: 39 (Abstrakt 52).
    14. Melekos MD, Asbach HW, Gerharz E, Naber KG. Post-intercourse versus daily ciprofloxacin prophylaxis for reccurent UTIs in premenopausal women. J Urol 1997; 157: 935. Go to original source... Go to PubMed...
    15. Naber KG, Bergman B, Bishop MC, Bjerklund Johansen TE, Botto H, Lobel B, Jimenez Cruz F, Selvaggi FP. Guidelines of Urinary and Male Genital Tract Infections. European Association of Urology (Update March 2004)(http://www.uroweb.org).
    16. Nicolle LE, Bjornson J, Harding GKM et al. Bacteriuria in elderly institutionalized men. N Engl J Med 1983; 309: 1420. Go to original source... Go to PubMed...
    17. Raz R, Stamm WE. A controlled trial in intravaginal estriol in postmenopausal women with recurrent urinary tract infection. New Engl J Med 1993; 329: 753-756. Go to original source... Go to PubMed...
    18. Safir MH, Schaeffer AJ. Urinary tract infections:Simple and complicated. AUA Update Series 1997; Volume 16, Lesson 10.
    19. Schaeffer AJ. Infections of the urinary tract. In: Campbell´s Urology CD-Rom, Walsh PC, Retik AB, Vaughan ED, Wein AJ, Volume 1, Section 4, Chapter 14, Copyright 2002, Elsevier Science (USA).
    20. Stapleton A, Latham RH, Johnson C et al Postcoital antimicrobial prophylaxis for recurrent urinary tract infection. A randomized, double-blind, placebo-controlled trial. JAMA 1990; 264:703-706. Go to original source... Go to PubMed...
    21. Vosti KL. Recurrent UTI´s: prevention by prophylactic antibiotics after sexual intercourse. JAMA 1990; 264: 703-706. Go to PubMed...
    22. ##
    23. Čermák A, Pacík D. Inkontinence moči. Praha: Kroměříž: Triton, 2006.
    24. Hanuš T. Epidemiologie inkontinence moči. Urologické listy, 2004; 1: 15.
    25. Chmel R. Ženská močová inkontinence. Practicus, 2003; 7: 12.
    26. Štěpán J. Jednorázové absorpční prostředky pro inkontinenci moči. Remedia, 2006; 6: 578-583.
    27. Zikmund J. Inkontinence moči u žen. Praha: Karolinum, 2001.
    28. ##
    29. Abrams P, Cardozo L, Fall M et al. The standardization of terminology of lower urinary tract function: Report from the Standardization Subcommittee of the ICS. Am J Obstet Gynecol 2002, 187(1): 116-126. Go to original source... Go to PubMed...
    30. Abrams P, Hanno P, Wein A. Overactive bladder and painful bladder syndrome: There need not be confusion. Neurourol Urodyn 2005; 24: 149-150. Go to original source... Go to PubMed...
    31. Cartwright R, Cardozo L. Transdermal oxybutynin: sticking to the facts. Eur. Urol 2007; 51(4): 907-914. Go to original source... Go to PubMed...
    32. Hashim H, Abrams P. Is the bladder a reliable witness for predicting detrusor overactivity? J Urol 2006; 175(1): 191-194. Go to original source... Go to PubMed...
    33. Chapple Ch et al. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: results of the stars trial, Eur Urol 2005; 48(3): 464-470. Go to original source... Go to PubMed...
    34. Chapple CR, Artibani W, Cardozo LD, Castro-Diaz D, Craggs M, Haab F, Khullar V, Versi E. The role of urinary urgency and its measurement in the overactive bladder symptom syndrome: current concepts and future prospects. BJU Int. 2005 Aug; 95(3): 335-340. Go to original source... Go to PubMed...
    35. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuskarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol 2005; 48: 5-26. Go to original source... Go to PubMed...
    36. Milsom I, Abrams P, Cardozo L, Roberts RG, Thuroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study, BJU Int 2001; 87: 760-766. Go to original source... Go to PubMed...
    37. Smith CP, Chancellor MB. Emerging role of botulinum toxin in the management of voiding dysfunction. J Urol 2004; 171: 2128-2137. Go to original source... Go to PubMed...
    38. ##
    39. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower tract function: report from the standardisation sub-committeee of the International Continence Society. Neurourol and Urodyn 2002; 21 (5): 1670-1678. Go to original source... Go to PubMed...
    40. Anderson K. Pharmacological treatment of urinary incontinence. Abrams P, Cardovo L, Khoury S, Sein A. 2nd Consultation on Incontinence, Paris 2001.
    41. Anderson KE, Bengtsson B, Paulsen O Desamino-8-D-arginine vasopresin (DDAVP). Pharmacology and clinical use. Drugs of today 1988; 24: 509.
    42. Anderson KE. Alpha-adrenoreceptors and benign prostatic hyperplasia: basic principles for treatment with alpha-adrenoreceptor antagonists. Word J Urol 2002; 19 (6): 390. Go to original source... Go to PubMed...
    43. Appell R, Sand P, Dmochowski R et al. Prospective randomised controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: resultsof OBJECT study. Mayo Clin Proc 2001; 76 (2): 358-363. Go to original source...
    44. Artibani W. Overactive bladder: new perspectives. Eur Urol 2002; Suppl. 4 (1): 1-30. Go to original source...
    45. Berghmans L, Hendriks H, De Bie R et al. Conservative treatment of urge urinary incontinence in women: a systematic review of randomized clinical trials. BJU Int 2000; 85 (2): 254-263. Go to original source... Go to PubMed...
    46. Bushman W, Steers WD, Meythaler JM. Voiding dysfunction in patiens with spastic paraplegie: urodynamic evaluation and response to continuous intrathecal baclofen. Neurourol Urodyn 1993; 12: 163. Go to original source... Go to PubMed...
    47. Castelden CM, George CF, Renwick AG et al. Imipramine - a possible alternative to current therapy for urinary incontinence in the elderly. J Urol 1981; 125: 218-221. Go to original source... Go to PubMed...
    48. Cole A, Fried F. Favorable experiences with imipramine in the treatment of neurogenic bladder. J Urol 1972; 107: 44-48. Go to original source... Go to PubMed...
    49. Collas D, Mallone - Lee J. The pharmacokinetic properties of rectal oxybutynin a possible alternative to intravesical administration. Neurourol Urodyn 1997; 16 (4): 346-347.
    50. Diokno A, Appell R, Sand P et al. Prospective, randomised, double - blind study of the efficacy and tolerabilty of the extended - release formulations of oxybutynin and tolterodine for overactive bladder. Results of the OPERA trial. Mayo Clin Proc 2003; 78 (4): 687-695. Go to original source... Go to PubMed...
    51. Michel MC. Fesoterodine: A novel muscarinic receptor antagonist for the treatment of overactive bladder syndrome. Expert Opin Pharmacother 2008; 9: 1787-1796. Go to original source... Go to PubMed...
    52. Milson I, Abrams P, Cardozo L et al. How widespread are the symptom sof an overactive bladder and how are they manager? A population-based prevalence study. BJU Int 2001; 87: 760-6. Go to original source... Go to PubMed...
    53. Tailor MC, Bates CP. A double blind crossover trial fo Baclofen - a new treatment for unstable bladder syndrome. Br JUrol 1979; 51: 504. Go to original source...
    54. 3rd International Consultation on Incontinence, Monaco 2005, June 25-26.
    55. Vrtal R, Vidlář A, Študent V. Diagnostika a léčba hyperaktivního měchýře. Urolog. pro Praxi, 2007; 8(5): 211-216.
    56. ##
    57. Asplund R. The nocturnal polyuria syndrome (NPS) Gen Pharmac 1995, 26 (6): 1203. Go to original source... Go to PubMed...
    58. Asplund R, Sundberg B, Bengtsson P. Oral desmopressin for nocturnal polyuria in elderly subjects: a double-blind placebo-controlled randomized exploratory study. BJU Int 1999, 83: 591-595. Go to original source... Go to PubMed...
    59. Carter PG. The role of nocturnal polyuria in nocturnal urinary symptomes in healthy elderly males 1992, MD thesis, Bristol.
    60. Chute CG, Panser LA, Girman CJ et al. The prevalence of prostatism: a population based survay of urinary symptoms. J Urol 1993, 150: 85-89. Go to original source... Go to PubMed...
    61. Djavan B, Milani S, Davies J et al. The impact of tamsulosin oral controlled absorption system (OCAS) on nocturia and the quality of sleep: preliminary results of a pilot study. Eur Urol Suppl 2005, 4 (2): 61-68. Go to original source...
    62. Donovan CG, Abrams P, Peters TJ et al. The ICS-,,BPH" Study: the psychometric validity and reliability of the ICS male questionnaire. Br J Urol 1996, 77: 554-562. Go to original source... Go to PubMed...
    63. Hald T, Nordling J, Andersen JT, Bilde T, Meyhoff HH, Walter S. A patient weighted symptom score system in the evaluation of uncomplicated benign prostatic hyperplasia. Scand J Urol Nephrol Suppl 1991, 138: 59-62. Go to original source...
    64. Jackson S, Donovan J, Brookes S, Eckford S, Swithinbank L, Abrams P. The Bristol female lower urinary tract symptoms questionnaire: development and psychometric testing. Br J Urol 77: 805-812.
    65. Kirkland JL, Lye M, Levy DW, Banerjee AK. Patterns of urine flow and electrolyte excretion in healthy elderly people. BMJ 1983, 287 (6406): 1665-1667. Go to original source... Go to PubMed...
    66. Kuo HC. Efficacy of desmopressin in treatment of refractory nocturia in patients older than 65 years. Urology 2002, 59 (4): 485-489. Go to original source... Go to PubMed...
    67. Lose G, Lalos O, Freeman RM et al. Efficacy of desmopressin (Minirin) in the treatment of nocturia: a double-blind placebocontrolled study in women. Am J Obstet Gynecol 2003, 189 (4): 1106-1113. Go to original source... Go to PubMed...
    68. Mattiasson A. Nocturia: towards a consensus. BJU 1999 Suppl 1, Vol 84. Go to original source... Go to PubMed...
    69. Mattsson S. Urinary incontinence and nocturia in healthy schoolchildren. Acta Paediatr 1994, 83: 950-954. Go to original source... Go to PubMed...
    70. Malmsten UG, Milsom I, Molander U, Norlen LJ. Urinary incontinence and lower urinary tract symptoms: an epidemiological study of men aged 45 to 99 years. J Urol 1997, 158: 1733-1737. Go to original source... Go to PubMed...
    71. Middlekoop HA, Smilde van den Doel DA, Neven AK, Kamphuisen HA, Springer CP. Subjective sleep characteristics of 1485 males and females aged 50-93: effects of sex and age, and factors related to self evaluated quality of sleep. J Gerontol A Biol Sci Med 1996, 51: 108-115. Go to original source... Go to PubMed...
    72. Rembratt A, Robertson GL, Norgaard JP, Andersson KE. Pathogenic aspects of nocturia in the elderly: Differences between nocturics and non-nocturics. ICS meeting 2000.
    73. Robertson G, Rembratt A, Eriksson KE. Desmopressin in the treatment of disorders of urine output in humans. Arch Int Med 2000.
    74. Robertson GL. Diabetes insipidus, in Endocrinology and metabolism clinics of North America 1995, 24 (3): 549-572. Go to original source... Go to PubMed...
    75. Swithinbank LV, Donovan J, James MC, Yang Q, Abrams P. Female urinary symptoms: age prevalence in a community dwelling population using a validated questionnaire. Neurourol Urodyn 1998, 16: 432-434.
    76. Thorpy MJ. International classification of sleep disorders: diagnostic and coding manual. Rochester MN 1990, American Sleep Disorders Association. van Kerrebroeck P, Weiss JP. Standardisation and terminology of nocturia. In: Mattiasson A (Ed): Nocturia towards a consensus. BJU Suppl 1 1999, Vol 84: 1-4. Go to original source...
    77. Weiss JP, Blaivas JG. Nocturia. J Urol 2000, 163: 5-12. Go to original source... Go to PubMed...
    78. Weiss JP, Blaivas JG, Stember DS, Brooks MM. Nocturia in adults: etiology and classification. Neurourol Urodyn 1998, 17: 467-472. Go to original source... Go to PubMed...
    79. ##
    80. Brock G, Chan J, Carrier S, Chan M, Salgado L, Klein AH, Lang C, Horner R, Gutkin S, Dickson R. The treatment of erectile dysfunction study: focus on treatment satisfaction of patients and partners. BJU Int 2007; 99: 376-382. Go to original source... Go to PubMed...
    81. Carson CC. PDE5 inhibitors: are there differences? Can J Urol 2006; 13 Suppl 1: 34-39.
    82. Kell PD, Hvidsten K, Morant SV, Harnett JP, Bridge S. Factors that predict changing the type of phosphodiesterase type 5 inhibitor medication among men in the UK. BJU Int 2007; 99: 860-863. Go to original source... Go to PubMed...
    83. Laumann EO, Nicolosi A, Glasser DB, Paik A, Gingell C, Moreira E, Wang T. Sexual problems among women and men aged 40-80 y: prevalence and correlates identified in the Global Study of Sexual Attitudes and Behaviors. Int J Impot Res 2005; 17: 39-57. Go to original source... Go to PubMed...
    84. Montorsi F, Padma-Nathan H, Glina S. Erectile function and assessments of erection hardness correlate positively with measures of emotional well-being, sexual satisfaction, and treatment satisfaction in men with erectile dysfunction treated with sildenafil citrate (Viagra). Urology 2006; 68: 26-37. Go to original source... Go to PubMed...
    85. Mulhall J, Althof SE, Brock GB, Goldstein I, Junemann KP, Kirby M. Erectile dysfunction: monitoring response to treatment in clinical practice-recommendations of an international study panel. J Sex Med 2007; 4: 448-464. Go to original source... Go to PubMed...
    86. Mulhall JP, Goldstein I, Bushmakin AG, Cappelleri JC, Hvidsten K. Validation of the Erection Hardness Score. J Sex Med 2007; 4: 1626-1634. Go to original source... Go to PubMed...
    87. Mulhall JP, McLaughlin TP, Harnett JP, Scott B, Burhani S, Russell D. Medication utilization behavior in patients receiving phosphodiesterase type 5 inhibitors for erectile dysfunction. J Sex Med 2005; 2: 848-855. Go to original source... Go to PubMed...
    88. Sivalingam S, Hashim H, Schwaibold H. An overview of the diagnosis and treatment of erectile dysfunction. Drugs 2006; 66: 2339-2355. Go to original source... Go to PubMed...
    89. Wespes E. Erectile dysfunction, physiologic approach, diagnosis and therapy. Bull Mem Acad R Med Belg 2006; 161: 151-158.
    90. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU Guidelines on erectile dysfunction: an update. Eur Urol 2006; 49: 806-815. Go to original source... Go to PubMed...
    91. ##
    92. Abrams PH, Shah PJ, Stone AR, Choa RG. Bladder outflow obstruction treated with phenoxybenzamine. Br J Urol 1982; 54: 527-530. Go to original source... Go to PubMed...
    93. Andriole GL, Guess HA, Epstein JL, et al. Treatment with finasteride preserves usefulness of prostate specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficiency and Safety Study. Urology 1998; 52: 195-201. Go to original source... Go to PubMed...
    94. AUA. American Urological Association guidelines on management of benign prostatic hypeplasia, 2003. http://www.auanet.org.
    95. Ball AJ, Feneley RC, Abrams PH. The natural history of untreated prostatism. Br J Urol 1981; 53: 613-616. Go to original source... Go to PubMed...
    96. Bartsch G, Rittmaster RS, Klocker H. Dihydrotestosterone and the concept of 5-alpha reductase inhibition in human benign prostatic hyperplasia. World J Urol 2002; 19: 413-425. Go to original source... Go to PubMed...
    97. Bruskewitz R, Girman CJ, Rowler J, et al. Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group (Proscar Long-term Efficasy and Safety Study). Urology 1999; 54(4): 670-678. Go to original source... Go to PubMed...
    98. de la Rosette J, Madersbacher S, Alivizatos G, et al. Guidelines EAU pro diagnostiku a léčbu benigní hyperplazie prostaty, EAU. Urol Listy 2004; 4: 71-103.
    99. Djavan B, Marberger M. A meta-analysis on the efficiency and tolerability oh alpha 1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia obstruction. Eur Urol 1988; 36: 1-13. Go to original source... Go to PubMed...
    100. Dvořáček J. Urologie praktického lékaře. Praha: ISV, 2000.
    101. European Association of Urology guidelines on benign prostatic hyperplasia (update March 2004).
    102. Hanno PM, Malkowicz SB, Wein AJ. Clinical manual of urology. Mc-Graw-Hill, New York 2001; 437-470.
    103. Hora M. Fytopreparáty v léčbě BPH. Urol Listy 2004; 4: 42-45.
    104. Isaacs JT. Importace of the natural history of benign prostatic hyperplasia in the evaluation of pharmacologic intervention. Prostate 1990; 3(Suppl): 1-7. Go to original source... Go to PubMed...
    105. Kaplan SA, Slawin KM, Te AE. Benign prostatic hyperplasia: New diagnostic and treatment paradigma. AUA Annual Meeting, San Antonio 2005.
    106. Klečka J, Hora M, Běhounek P. Kombinovaná léčba benigní hyperplazie prostaty, ano či ne? Urolog. pro Praxi 2008; 9(2): 54-60.
    107. Kolombo I, et al. Benigní hyperplazie prostaty - BPH. Urolog. pro Praxi, 2008; 9(3): 138-142.
    108. Kolombo I. EUNI-Benigní hyperplázie prostaty. www.euni.cz.
    109. Mc Connell JD. The long term effects of medical therapy on progression of BPH: Results from the MTOPS trial. J Urol 2002; 167: 265, abstract 1042. Go to PubMed...
    110. Oesterling JE, Roy J, Agha A, Shown T, Kralup T, Johansen T, Lagerkvist M, Gormley G, Bach M, Waldstreicher J. Biologic variability of prostate specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology 1997; b50: 13-18. Go to original source... Go to PubMed...
    111. PDR Electronic Library. Physician Desk Reference 2004. Thomson Medical Economics. CD-ROM.
    112. Schwinn DA. The role of sloha-1-adrenergic receptor subtypes in lower urinary tract symptoms. Br J Urol 2001; 88: 27-34. Go to original source... Go to PubMed...
    113. Verner P. Benigní hyperplazie prostaty. Praha: Remedia, 2004; 24(4): 346-354.
    114. Verner P. Benigní hyperplazie prostaty. Současný přístup k farmakologické léčbě. Praha: Maxdorf, 2005.

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.